

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/553,594 Conf. #6064	
			Filing Date	July 30, 2007	
			First Named Inventor	Richard L. BOYD	
			Art Unit	1644	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	5	Attorney Docket Number	0286336.00159US2 (NOR-020US)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA*	US-5,824,322	10-20-1998	Balasubramanian	
	AB*	US-2002/0136704	09-26-2002	Boyd	
	AC*	US-2003/0017153	01-23-2003	Boyd	
	AD*	US-6,368,636	04-09-2002	McIntosh et al.	
	AE*	US-2002/0159999	10-31-2002	Sykes	
	AF*	US-6,863,885	03-08-2005	Mardiney, III et al.	
	AG*	US-6,544,747	04-08-2003	Haynes et al.	
	AH*	US-5,650,306	07-22-1997	Nabel et al.	
	AIK*	US-6,776,986	08-17-2004	Boehnlein et al.	
	AJ*	US-6,232,120	05-15-2001	Dropulic et al.	
	AK*	US-4,049,805	09-20-1977	Strade	
	AL*	US-5,759,551	06-02-1998	Ladd et al.	
	AJ*	US-2003/0165475	09-04-2003	Ildstad	
	AK*	US-6,544,787	04-08-2003	Slavin et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-03/051272	06-26-2003	Yeda Res & Dev et al.		
	BB	WO-96/06642	03-07-1996	The General Hospital Corporation		
	BC	EP-0882736	12-09-1988	Laboratoire Theramex, S.A.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/553,594 Conf. #6064	
			Filing Date	July 30, 2007	
			First Named Inventor	Richard L. BOYD	
			Art Unit	1644	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	5	Attorney Docket Number	0286336.00159US2 (NOR-020US)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	GREENWAY, Brian A., "Effect of Flutamide on Survival in Patients with Pancreatic Cancer: Results of a Prospective, Randomised, Double Blind Placebo Controlled Trial," BMJ Volume 316, June 27, 1998 (pages 1935-1938)	
	CB	JACOBSON, Jill et al., "Modulation of the Expression of Murine Lupus by Gonadotropin-Releasing Hormone Analogs," Endocrinology, Vol. 134, No. 6 (pages 2516-2523)	
	CC	NERI, Christian et al., "Direct Inhibiting Effects of [D-Trp ⁶] Gonadotropin-releasing Hormone on the Estrogen-sensitive Progression of Polyoma Virus-induced Mammary Tumors in Athymic Mice," Cancer Research 50, 5891-5897, September 15, 1990	
	CD	OLSEN, Nancy J., "Induction of Immature Thymocyte Proliferation after Castration of Normal Male Mice," Endocrinology, Vol. 134, No. 1, 1994 (pages 107-113)	
	CE	VAN GRIENSVEN, M., et al., "Differential Effects of Sex Hormones on Autoantibody Production and Proteinuria in Chronic Graft-Versus-Host Disease-Induced Experimental Lupus Nephritis," 1997 Blackwell Science Ltd., Clinical and Experimental Immunology, 107:254-260	
	CF	AUSTIN, Timothy W., et al., "Long-term Multilineage Expression in Peripheral Blood from a Moloney Murine Leukemia Virus Vector After Serial Transplantation of Transduced Bone Marrow Cells," Blood, Volume 95, Number 3, February 1, 2000, pages 829-836	
	CG	BBC News Health, "The Castration Cure," December 1998, pages 1-2	
	CH	MUSEY et al., "Cytotoxic-T-Cell Responses, Viral Load, and Disease Progression in Early Human Immunodeficiency Virus Type 1 Infection," New England Journal of Medicine, Vol. 337, 1997, pages 1267-1274	
	CI	NAKANISHI et al., "Cytotoxic T Cell Function in Fish," Developmental and Comparative Immunology, Vol. 26, 2002, pages 131-139	
	CJ	DEANESLY et al., "The Structure and Development of the Thymus in Fish, with Special Reference to Salmo Fario," Journal of Cell Science, Vol 281, 1927, pages 113-145	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/553,594 Conf. #6064
				Filing Date	July 30, 2007
				First Named Inventor	Richard L. BOYD
				Art Unit	1644
				Examiner Name	Not Yet Assigned
Sheet	3	of	5	Attorney Docket Number	0286336.00159US2 (NOR-020US)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CK	COOPER, Max D., et al., "The Functions of the Thymus System and the Bursa System in the Chicken," Pillars of Immunology, The Journal of Experimental Medicine, Vol. 123, 1966, 35 pages	
	CL	BRAAK, H., "Stages in the Development of Parkinson's Disease-Related Pathology," Cell Tissue Res. Vol. 318, pages 121-134	
	CM	RINGHEIM, G.E., "Brain Inflammation, Cholesterol, and Glutamate as Interconnected Participants in the Pathology of Alzheimer's Disease," Current Pharmaceutical Design, Vol. 12, 2002, pages 719-738	
	CN	HUDSON VM, "Rethinking Cystic Fibrosis Pathology: The Critical Role of Abnormal Reduced Glutathione Transport caused by CFTR Mutation," Free Radical Biology and Med. Vol. 30, 2001, pages 1440-1461	
	CO	COLE-STRAUSS, A., "Correction of the Mutation Responsible for Sickle Cell Anemia by an RNA-DNA Oligonucleotide," 1996, Science, Vol. 273, pages 1386-1389	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/553,594 Conf. #6064	
			Filing Date	July 30, 2007	
			First Named Inventor	Richard L. BOYD	
			Art Unit	1644	
			Examiner Name	Not Yet Assigned	
Sheet	4	of	5	Attorney Docket Number	0286336.00159US2 (NOR-020US)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CP	TAKAMI et al., J. Heart Lung Transplant, 1995, 14:529-536	
	CQ	ANTUS et al., Transplant Institute, 2002, 15:494-501	
	CR	SCHOFIELD et al., J. Heart Lung Transplant, 2002, 21:493-495	
	CS	BOJAK et al., The Past, Present, and Future of HIV-Vaccine Development: A Critical Review," DDT 7:36-46, 2002	
	CT	MWAU et al., "A Review of Vaccines for HIV Prevention," J. Gene Med. 5:3-10, 2003	
	CU	DESROSIERS, R.C., "Prospects for an AIDS Vaccine," Nature Med. 10:221-223, 2004	
	CV	PANTALEO et al., "Correlates of Immune Protection in HIV-1 Infection: What We Know, What We Don't Know, What We Should Know," Nature Med. 10:806-810, 2004	
	CW	KONG, Fan-Kun et al., "Reversible Disruption of Thymic Function by Steroid Treatment," The Journal of Immunology, Copyright 2002 by The American Association of Immunologists, Inc., pages 6500 - 6505	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/553,594 Conf. #6064
				Filing Date	July 30, 2007
				First Named Inventor	Richard L. BOYD
				Art Unit	1644
				Examiner Name	Not Yet Assigned
Sheet	5	of	5	Attorney Docket Number	0286336.00159US2 (NOR-0120US)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CX	KONDO, Yasuhiro et al., "Effects of Estrogen Treatment During the Embryogenic Protocol Period on Chick Antibody Production," Journal of Poultry Science, 41: 85-93, 2004	
	CY	IMANISHI, Masaaki, "Induction of Tolerance by Intrathymic Injection of Donor Bone Marrow Cells and Its Mechanism," March 11, 1996, 9 pages	
	CZ	DUPONT, A., et al., "Combination Therapy with Flutamide and the LHRH Agonist [D-Trp ⁶ , des-Gly-NH ₂ ¹⁰] LHRH Ethylamide in Stage C Prostatic Carcinoma," British Journal of Urology (1993), 72, 629-634	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.